Vaccines Weekly Update - July 18th 2025

🔬💉 Vaccines Global Breakthroughs: Clinical Updates From India to the EU and More 🌍💉🧬

In this week’s edition of Vaccine Research Updates, brought to you by LucidQuest, we dive into critical milestones shaping global immunization strategies and public health preparedness. Whether you’re a healthcare strategist, clinical scientist, or biotech innovator, these developments are essential:

💉 Pfizer’s HER2+ ADC Trial in India: CDSCO approves Phase 3 study for Disitamab Vedotin targeting HER2-positive gastric and urothelial cancers—expanding access to precision oncology.

🦟 India’s First Dengue Vaccine Nears Phase 3 Completion: Panacea Biotec’s DengiAll, developed with ICMR, is wrapping enrolment of 10,500 participants across 20 centers—delivering single-dose protection against all four dengue serotypes.

🌐 Osivax’s Dual-Flu Strategy Validated: Phase 2a results confirm strong nucleoprotein-specific immunity when OVX836 is co-administered with Fluarix Tetra—paving the way for broader, more durable flu protection.

🧠 UNM Launches Alzheimer’s Vaccine Trial: A new tau-targeting vaccine using VLP technology begins Phase 1a/1b. Backed by a $1M Alzheimer’s Association grant, the trial builds on preclinical success with cognitive recovery.

🛡️ GSK Aims to Expand RSV Coverage: Arexvy filing seeks FDA approval for adults aged 18–49 at risk. With Phase IIIb data and over 21 million under-50 Americans at risk, this expansion could reshape RSV prevention.

👶 Moderna’s Spikevax Approved for At-Risk Children: The FDA grants full approval for use in children 6 months to 11 years with comorbidities—enhancing pediatric COVID-19 protection nationwide.

🍁 SK Bioscience Files IND for High-Immunogenicity Flu Vaccine: NBP607B, Korea’s first adjuvanted SKYCellflu-based candidate, targets global market entry by 2027 with Phase 1/2 trials on the horizon.

🇪🇺 Bavarian Nordic Signs €27M EU Deal for Mpox/Smallpox Vaccine: MVA-BN vaccine order adds to 2025 preparedness contracts now exceeding 3 billion Danish kroner—about 430 million U.S. dollars.

📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine innovations and global immunization progress

#VaccineResearch #DengueVaccine #AlzheimersVaccine #FluVaccine #Moderna #PfizerIndia #SKBioscience #BavarianNordic #RSVVaccine #LucidQuest #LQVentures #ClinicalTrials #GlobalHealth #PublicHealth #InfectiousDiseases #BiotechInnovation #COVID19 #UniversalFlu #NeurologyResearch #HealthcareConsulting #ImmunizationUpdates